Are There Any Side Effects to the Pneumonia Vaccine for Seniors?

Pneumonia vaccines are among the safest vaccines available for older adults, and most side effects are mild and short-lived. The most common reactions include soreness or redness at the injection site, fatigue, headache, and muscle aches, with the vast majority resolving within a day or two. Serious adverse events are rare, but they do exist, and understanding what to expect can make a real difference in whether someone decides to get vaccinated or skip it out of fear.

What the Typical Side Effects Look and Feel Like

If you’re 65 or older and get a pneumococcal vaccine, the side effect you’re most likely to notice is some soreness, redness, or swelling where the needle went in. Post-marketing surveillance of the newer 20-valent pneumococcal conjugate vaccine (PCV20) found that among adults aged 65 and older, injection-site reactions were the single most common complaint, reported in about a third of cases tracked through the national reporting system.¹ Beyond the injection site, the systemic side effects people commonly report include fever or chills, loss of appetite, fatigue, headache, and muscle or joint aches.²

These aren’t just theoretical possibilities listed on a package insert. In pooled safety data from clinical trials of the newest 21-valent conjugate vaccine (PCV21), about 63% of recipients reported at least one side effect, a rate essentially identical to the 64% seen in people who received older comparison vaccines. Injection-site pain topped the list at roughly 56%. Among whole-body symptoms, fatigue affected about 27% of PCV21 recipients, headache about 18%, and muscle pain about 11%. The overwhelming majority of these were graded as mild or moderate.³

For most people, these symptoms show up within hours of the shot and fade by the next day. A sore arm that lasts two or three days is on the longer end of normal. Fever, when it occurs, is usually low-grade. The picture is similar regardless of which pneumococcal vaccine formulation you receive, though the specific percentages shift slightly between vaccine types.

Why a Second Dose Can Sting More

One thing that catches some seniors off guard is that a revaccination can produce a stronger local reaction than the first dose. A study comparing adults receiving their first pneumococcal polysaccharide vaccination with those getting a repeat dose found that about 11% of revaccinated individuals developed a large local reaction (roughly four inches or more in diameter) within two days, compared to just 3% of first-time recipients. Among healthy, immunocompetent revaccinated adults without chronic illness, the rate climbed to 15%.⁴

The reason is straightforward: if your immune system already has antibodies from a previous dose, those pre-existing antibodies react when they encounter the vaccine antigens again. The study found that the risk of a large local reaction correlated with how high a person’s antibody levels were before the booster. Higher pre-vaccination antibody levels meant a bigger local response. The reassuring news is that these reactions resolved quickly, with a median duration of about three days. They looked dramatic but were not dangerous.

This is worth knowing because some seniors and even some healthcare providers have been reluctant to give repeat pneumococcal doses, worried about triggering a bad reaction. The evidence shows the reactions are bigger but still self-limiting. They do not signal a systemic problem or a reason to avoid future vaccination.

Serious Adverse Events Are Uncommon

The word “serious” in vaccine safety has a specific meaning: it generally covers events requiring hospitalization, causing lasting disability, or being life-threatening. In long-term surveillance of the older polysaccharide vaccine (PPSV23) through the U.S. reporting system from 1990 to 2013, about 8% of all reports were classified as serious. The vast majority of reports, around 92%, were non-serious. Fever was the most commonly flagged symptom in serious reports. A review of 66 death reports filed during that period found no concerning pattern that would link the deaths to the vaccine itself.⁵

For the newer PCV21 vaccine, pooled clinical trial data showed serious adverse events in 1.5% of vaccine recipients over six months of follow-up, compared to 2.0% in the group that received an older comparison vaccine. Only two of those serious events were judged to be actually caused by the vaccine: one case of bronchospasm and one of injection-site cellulitis, both of which resolved.³ Four people across the trials developed fevers of 104°F or higher, which sounds alarming but all resolved without lasting harm.

Anaphylaxis and Guillain-Barré Syndrome

Two rare but headline-grabbing adverse events deserve their own discussion because they tend to fuel vaccine hesitancy out of proportion to their actual risk.

Anaphylaxis, a severe whole-body allergic reaction, can theoretically occur with any vaccine. But pneumococcal vaccines have one of the lowest anaphylaxis rates among all routinely administered vaccines, estimated at about 0.9 cases per 100,000 recipients.⁶ To put that in perspective, you face roughly the same odds every time you take a common over-the-counter pain reliever. Anaphylaxis is treatable on the spot with epinephrine, which is why vaccination sites are required to have it on hand, and the 15-minute observation period after your shot exists precisely for this scenario.

Guillain-Barré syndrome (GBS), a condition where the immune system attacks the nerves and causes weakness or paralysis, has been flagged as a potential safety signal with PCV20. Post-marketing surveillance identified a reporting rate of about 0.5 cases per million doses distributed. Among the 20 reports filed, 11 were verified as genuine GBS, and 7 of those were in adults 65 or older. The median time from vaccination to symptom onset was 14 days. It’s also worth noting that half of the verified GBS patients had received another vaccine at the same visit, making it difficult to pin the GBS on the pneumococcal vaccine specifically.⁷ This signal is still being studied, and regulators have not changed their recommendations based on it. But if you’ve had GBS before, it’s worth discussing the pneumococcal vaccine with your doctor.

How Real-World Reporting Data Compares to Clinical Trials

Clinical trials enroll carefully selected volunteers, track them closely, and report side effects in percentages. The real world is messier. The primary tool for tracking vaccine safety after a product reaches the market in the United States is VAERS, the Vaccine Adverse Event Reporting System. Anyone can file a report, which means the data captures everything from genuine reactions to coincidental health events that happened to occur after vaccination.

A large-scale analysis of the VAERS database covering all pneumococcal vaccines found over 157,000 individuals in the system with more than 632,000 adverse event reports. The most commonly flagged events were injection-site redness, injection-site swelling, and injection-site pain, consistent with what clinical trials show. Most events occurred on the same day as vaccination or within the first 30 days. About 44% of people in the database were recorded as having fully recovered, while roughly 15% were hospitalized at some point.⁸

That hospitalization figure can look alarming if you don’t understand how VAERS works. The system captures reports from people who happened to be hospitalized for any reason in the period after vaccination. An older adult hospitalized for a fall or a heart problem who also recently got a pneumococcal shot may appear in VAERS without the hospitalization having anything to do with the vaccine. VAERS is a signal-detection tool, not a cause-and-effect database. The clinical trial data and dedicated surveillance reviews consistently show that the actual rate of vaccine-caused serious events is far lower than raw VAERS numbers might suggest.

Women Report More Side Effects Than Men

An interesting and consistent pattern across pneumococcal vaccine surveillance is that women file more adverse event reports than men. In VAERS data, females accounted for about 54% of reports compared to roughly 37% for males.⁸ A similar pattern showed up in the older PPSV23 surveillance data, where 67% of all reports were from women.⁵

This isn’t unique to pneumococcal vaccines. Women tend to report stronger immune responses to many vaccines, likely due to hormonal and genetic differences that make the female immune system more reactive on average. For a senior woman, this might mean a slightly more noticeable sore arm or a bit more fatigue, but it does not mean a higher risk of serious harm. The gap is one of perception and reporting as much as it is one of biology. Women are also more likely to report adverse events in general, which inflates the apparent difference.

How Aging Changes the Side Effect Picture

Older immune systems behave differently from younger ones. The gradual decline in immune function that comes with aging, sometimes called immunosenescence, means that seniors tend to mount a weaker immune response to vaccines than younger adults.⁹ Paradoxically, this often translates into fewer and milder side effects, not more. Side effects are largely a byproduct of your immune system gearing up in response to the vaccine. A weaker immune response can mean less of that inflammatory surge that causes soreness, fatigue, and fever.

This creates a somewhat confusing situation: the people who need pneumococcal vaccination most (older adults with weaker immune systems) are the same people who may get the least robust protection from it and also experience the fewest side effects. A complete absence of side effects doesn’t mean the vaccine didn’t work. But it does help explain why many seniors report barely noticing they got the shot, while their 50-year-old neighbors might feel wiped out for a day. The clinical trial data for PCV21 bears this out: side effect rates in vaccine-experienced adults aged 50 and older were comparable to or lower than those in younger vaccine-naive adults.³

Common Misconceptions That Keep Seniors From Getting Vaccinated

Research into vaccine attitudes among older adults has consistently found that concerns about side effects are one of the top reasons seniors avoid or delay pneumococcal vaccination. A study focused on educating older adults about influenza and pneumococcal vaccines found that participants held “many misconceptions” about both the diseases and their vaccines, with side-effect fears featuring prominently.¹⁰

A few of these misconceptions come up repeatedly:

The vaccine can give you pneumonia. Pneumococcal vaccines contain no live bacteria. They cannot cause the infection they’re designed to prevent. If you develop a respiratory illness shortly after vaccination, it was either already incubating or caused by a different pathogen.
Side effects mean something went wrong. A sore arm and mild fatigue are signs your immune system is responding to the vaccine, which is exactly what it’s supposed to do. The absence of side effects doesn’t mean the vaccine failed, and their presence doesn’t mean you’re having a bad reaction.
You only need one pneumococcal shot in your lifetime. Vaccination guidelines have changed over the years, and many seniors who received an older formulation years ago are now recommended to get one of the newer conjugate vaccines. The updated vaccines cover more bacterial strains. A second dose of a different vaccine type isn’t the same as an unnecessary repeat.
The side effects are worse for older people. As discussed above, the opposite tends to be true. Older adults generally experience milder reactions than younger adults, though individual experiences vary.

These misconceptions have real consequences. Pneumococcal disease kills thousands of older adults every year in the United States, and vaccination rates among seniors remain lower than public health targets. Fear of side effects that are, in the vast majority of cases, mild and brief contributes to that gap.

Newer Vaccines and What They Mean for Side Effects

The pneumococcal vaccine landscape has been evolving rapidly. For years, the two main options were PPSV23 (a polysaccharide vaccine covering 23 bacterial strains) and PCV13 (a conjugate vaccine covering 13 strains). More recently, PCV15, PCV20, and PCV21 have entered the picture, each covering more strains. With each new formulation comes the question of whether more antigens mean more side effects.

So far, the answer appears to be no, at least not in any clinically meaningful way. The PCV21 trials showed that side effect rates were essentially the same whether participants received PCV21 or an older vaccine as the comparator. The types of side effects were also the same: injection-site pain, fatigue, headache, and muscle aches, in that order of frequency.³ There were modest differences in some systemic symptoms: fatigue and headache were a few percentage points more common with PCV21 than with comparison vaccines. Whether that small difference reflects the additional antigens or just normal variation between trial populations is unclear.

For the earlier jump from PCV13 to PCV20, post-marketing surveillance similarly did not uncover any new categories of side effects beyond what was already known from the older vaccines.⁷ The GBS signal mentioned earlier is the one genuinely new safety question that has emerged, and it involves a vanishingly small number of cases relative to the millions of doses administered.

When to Call Your Doctor

The vast majority of side effects from pneumococcal vaccination need nothing more than an over-the-counter pain reliever and some patience. But certain symptoms after any vaccine warrant a call to your healthcare provider. Difficulty breathing, swelling of the face or throat, a widespread rash, a rapid heartbeat, or dizziness in the minutes to hours after vaccination could signal an allergic reaction. A fever above 104°F that doesn’t come down with acetaminophen or ibuprofen is worth reporting. And any new weakness or tingling in the arms or legs in the weeks following vaccination, while exceedingly unlikely, should be evaluated promptly because of the remote possibility of GBS.

For the typical senior, though, the experience of getting a pneumococcal vaccine looks like this: a brief pinch, a sore arm for a day, and maybe some tiredness that evening. Many people feel nothing at all. The side effects are real but manageable, and they are far milder than what pneumococcal pneumonia itself inflicts on an older body.